Showing 1 - 8 results of 8 for search 'W. Wierda', query time: 0.03s Refine Results
  1. 1
    PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.

    PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PH... by J. Burger, M. Sivina, E. Kim, G. Issa, W. Wierda, N. Jain, P. Thompson, A. Ferrajoli

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P651: VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY

    P651: VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY by P. Hampel, S. Parikh, W. Wierda, A. Ferrajoli, N. Jain, J. Burger, T. Call, Y. Wang, S. Kenderian, W. Ding, P. Thompson

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)

    P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) by T. Kadia, F. Ravandi, G. Borthakur, E. Jabbour, G. Montalban-Bravo, L. Adewale, S. Pierce, C. Lacke, M. Brandt, N. Short, N. Jain, J. Burger, A. Ferrajoli, W. Wierda, H. Kantarjian

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB

    P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB by W. Macaron, E. Jabbour, M. Konopleva, F. Ravandi, N. Jain, G. Issa, T. Kadia, K. Sasaki, P. Kebriaei, M. Yilmaz, P. Thompson, K. Takahashi, H. Abbas, W. Wierda, R. Garris, H. Kantarjian, N. Short

    Published 2022-06-01
    Get full text
    Article
  5. 5
    P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)

    P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBL... by F. Ravandi, E. Jabbour, N. Jain, T. Kadia, B. Gautam, M. Konopleva, W. Wierda, J. Burger, G. Issa, A. Maiti, H. Balkin, M. Kelly, R. Garris, P. Kebriaei, A. Ferrajoli, G. Garcia-Manero, Y. Alvarado, N. Short, H. Kantarjian

    Published 2022-06-01
    Get full text
    Article
  6. 6
    P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRIAL

    P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRI... by F. Haddad, H. Kantarjian, N. Short, F. Ravandi, N. Jain, W. Macaron, T. Kadia, Y. Alvarado, N. Daver, G. Borthakur, C. DiNardo, M. Konopleva, W. Wierda, J. Jacob, E. Roy, C. Loiselle, A. Milton, J. Rivera, R. Garris, E. Jabbour

    Published 2022-06-01
    Get full text
    Article
  7. 7
    S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY

    S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY by N. Short, H. Kantarjian, M. Konopleva, N. Jain, F. Ravandi, X. Huang, W. Macaron, W. Wierda, G. Borthakur, T. Kadia, K. Sasaki, G. Issa, G. Montalban-Bravo, Y. Alvarado, G. Garcia-Manero, C. Dinardo, J. Thankachan, R. Delumpa, E. Mayor, W. Deen, A. Milton, J. Rivera, L. Waller, C. Loiselle, R. Garris, E. Jabbour

    Published 2022-06-01
    Get full text
    Article
  8. 8
    S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

    S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION by N. Jain, P. Thompson, J. Burger, A. Ferrajoli, K. Takahashi, Z. Estrov, G. Borthakur, P. Bose, T. Kadia, N. Pemmaraju, K. Sasaki, M. Konopleva, E. Jabbour, N. Garg, X. Wang, R. Kanagal-Shamanna, K. Patel, W. Wang, S. Wang, J. Jorgensen, W. Lopez, A. Ayala, W. Plunkett, V. Gandhi, H. Kantarjian, S. O’Brien, M. Keating, W. Wierda

    Published 2022-06-01
    Get full text
    Article

Search Tools: